WO2006090365A3 - Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents - Google Patents

Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents Download PDF

Info

Publication number
WO2006090365A3
WO2006090365A3 PCT/IL2006/000216 IL2006000216W WO2006090365A3 WO 2006090365 A3 WO2006090365 A3 WO 2006090365A3 IL 2006000216 W IL2006000216 W IL 2006000216W WO 2006090365 A3 WO2006090365 A3 WO 2006090365A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligoamine
conjugates
polysaccharide
amyloid
viral agents
Prior art date
Application number
PCT/IL2006/000216
Other languages
French (fr)
Other versions
WO2006090365A2 (en
Inventor
Abraham J Domb
Ehud Katz
Ira Yudovin-Farber
Albert Taraboulos
Original Assignee
Yissum Res Dev Co
Abraham J Domb
Ehud Katz
Ira Yudovin-Farber
Albert Taraboulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Abraham J Domb, Ehud Katz, Ira Yudovin-Farber, Albert Taraboulos filed Critical Yissum Res Dev Co
Publication of WO2006090365A2 publication Critical patent/WO2006090365A2/en
Publication of WO2006090365A3 publication Critical patent/WO2006090365A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides the use of polysaccharide-oligoamine conjugates, compositions comprising thereof and methods of prophylaxis and/or treatment of viral diseases and diseases and disorders associated with accumulation of amyloid fibrils (amyloidoses).
PCT/IL2006/000216 2005-02-22 2006-02-21 Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents WO2006090365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65487005P 2005-02-22 2005-02-22
US60/654,870 2005-02-22

Publications (2)

Publication Number Publication Date
WO2006090365A2 WO2006090365A2 (en) 2006-08-31
WO2006090365A3 true WO2006090365A3 (en) 2007-02-22

Family

ID=36607225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000216 WO2006090365A2 (en) 2005-02-22 2006-02-21 Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents

Country Status (1)

Country Link
WO (1) WO2006090365A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103340881B (en) * 2013-07-09 2016-06-08 中国科学院上海药物研究所 The application in neuroprotective of a kind of oligosaccharide compound
PL235490B1 (en) * 2016-04-04 2020-08-24 Univ Jagielloński Application of cationic derivative of dextrane for retardation of HSV-1 viral replication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319144A1 (en) * 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
EP1222926A1 (en) * 2001-01-10 2002-07-17 Polygene Ltd. Cationic polysaccharide compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319144A1 (en) * 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
EP1222926A1 (en) * 2001-01-10 2002-07-17 Polygene Ltd. Cationic polysaccharide compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EBBENSEN P.: "Life Span, Leukemia and Amyloid Incidences of Untreated and Polycation-Treated AKR Mice", BRITISH JOURNAL OF CANCER, vol. 37, 1978, pages 76 - 80, XP008070308 *
SUPATTAPONE S. ET AL.: "Elimination of Prions by Branched Polyamines and Implications for Therapeutics", PNAS, vol. 96, no. 25, 1999, pages 14529 - 14534, XP002404008 *

Also Published As

Publication number Publication date
WO2006090365A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
CU20080044A7 (en) Pharmaceutical compositions for the treatment of disorders of the inner ear.
EP1893216A4 (en) Methods and compositions for the treatment of ocular disorders
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
IL188788A0 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
WO2006124748A3 (en) Multicyclic compounds and methods of their use
ZA200903604B (en) Methods,compositions,and kits for the treatment of medical conditions
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2008048288A3 (en) Novel nanoparticles and use thereof
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
NO20055130L (en) Aminocyclohexyl ether compounds and their use
IL214198A0 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
PL1799231T3 (en) Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
ITRM20050179A1 (en) APPLICABLE COMPOSITION FOR THE TREATMENT OF PARADONTAL DISEASES.
GB0523961D0 (en) The treatment of ophthalmic diseases
WO2006090365A3 (en) Polysaccharide-oligoamine conjugates as anti-amyloid and anti-viral agents
WO2008085927A3 (en) Methods, compositions, and kits for the treatment of pain
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0523964D0 (en) The treatment of ophthalmic diseases
NL1032065A1 (en) Preparation for the prevention and treatment of cardiovascular disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06711198

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6711198

Country of ref document: EP